NUTEX InvestmentsBUD:NUTEX -0.37%50 ROE % is 14.16% as of Dec. 2025, which is 2148% above its 10-year median of 0.63. GuruFocus rates BUD:NUTEX with a GF Score™ of 50/100 and a GF Value™ of Ft13.80 (Fairly Valued). The stock has 3 warning signs investors should review. Among 935 Drug Manufacturers companies, NUTEX Investments ranks better than 62.67% on this metric.
The historical rank and industry rank for NUTEX Investments's ROE % or its related term are showing as below:
BUD:NUTEX'
s ROE % Range Over the Past 10 Years
Min: -35.39 Med: 0.63 Max: 9.47
Current: 9.47
During the past 13 years, NUTEX Investments's highest ROE % was 9.47%. The lowest was -35.39%. And the median was 0.63%.
BUD:NUTEX's ROE % is ranked better than 62.67% of 935
companies
in the Drug Manufacturers industry
Industry Median: 6
vs BUD:NUTEX: 9.47
NUTEX Investments (BUD:NUTEX) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
NUTEX Investments ROE % Related Terms
NUTEX Investments ROE % Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's ROE % distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
NUTEX Investments (BUD:NUTEX) has a ROE % of 14.16% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on NUTEX Investments and its competitors. This is 2148% above median its historical median of 0.63. According to the industry distribution chart, NUTEX Investments ranks #349 out of 935 companies in the Drug Manufacturers industry, placing it in the top 37.3%.
Is NUTEX Investments' ROE % too high?
NUTEX Investments' current ROE % of 14.16% is 2148% above median its 10-year median of 0.63. The Drug Manufacturers industry median ROE % is 6.00. NUTEX Investments' value of 14.16% is 136% above this industry median. Based on the distribution chart, NUTEX Investments ranks #349 out of 935 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, NUTEX Investments has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #349 out of 935 companies for ROE %. This puts NUTEX Investments in the upper half of its industry. The industry median ROE % is 6.00. NUTEX Investments' value of 14.16% is 136% above this benchmark. While the company's 10-year median is 0.63 vs. the industry median of 6.00, NUTEX Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.00, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NUTEX Investments's current ROE % of 14.16% is 136% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current ROE % is 14.16%, which is 2148% above median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft13.40 — trading 2.9% below its estimated fair value. The current ROE % is 14.16%, which is 2148% above median its 10-year median of 0.63 and 136% above the Drug Manufacturers industry median of 6.00. NUTEX Investments' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current ROE % is 14.16% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?
Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued.
The current stock price of Ft13.40 is trading 2.9% below its estimated GF Value™ of Ft13.80.
GuruFocus considers NUTEX Investments to be Fairly Valued.
Key valuation signals for BUD:NUTEX:
ROE %: 14.16% (2148% above median its 10-year median of 0.63)
GF Value™: Ft13.80 vs. price of Ft13.40 (2.9% below fair value)
Industry Position: 136% above the Drug Manufacturers median (#349 of 935)
No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
50GF Score
Get the complete analysis for BUD:NUTEX
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
